Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell Non-Hodgkin’s Lymphoma: Results of the FAB/LMB 96 international study
Identifieur interne : 000030 ( Pmc/Checkpoint ); précédent : 000029; suivant : 000031Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell Non-Hodgkin’s Lymphoma: Results of the FAB/LMB 96 international study
Auteurs : Ha Poirel [France, Belgique] ; Ms Cairo [États-Unis] ; Na Heerema ; J. Swansbury [Royaume-Uni] ; A. Aupérin [France] ; E. Launay [France] ; Wg Sanger ; P. Talley [Royaume-Uni] ; Sl Perkins [États-Unis] ; M. Raphaël [France] ; K. Mccarthy [Royaume-Uni] ; R. Sposto [États-Unis] ; M. Gerrard [Royaume-Uni] ; A. Bernheim [France] ; C. Patte [France]Source :
- Leukemia [ 0887-6924 ] ; 2008.
Abstract
Clinical studies showed that advanced stage, high LDH, poor response to reduction therapy and combined bone marrow and central nervous system disease are significantly associated with a decreased event free survival (EFS) in pediatric mature B-NHL treated on FAB/LMB96. Although rearranged MYC/8q24 (R8q24) is characteristic of Burkitt Lymphoma (BL), little information is available on other cytogenetic abnormalities and their prognostic importance. We performed an international review of 238 abnormal karyotypes in childhood mature-B-NHL treated on FAB/LMB96: 76% BL, 8% Burkitt-like lymphoma, 13% diffuse large B-cell lymphoma (DLBCL). The main BL R8q24 associated chromosomal aberrations were +1q [29%], +7q and del(13q) [14% each]. The DLBCL appeared heterogeneous and more complex. Incidence of R8q24 [34%] was higher than reported in adult DLBCL. The prognostic value of cytogenetic abnormalities on EFS was studied by Cox model controlling for the known risk factors: R8q24, +7q and del(13q) were independently associated with a significant inferior EFS [HR: 6.1 (p=0.030), 2.5 (p=0.015), 4.0 (p=0.0003), respectively]. The adverse prognosis of R8q24 was observed only in DLBCL while del(13q) and +7q had a similar effect in DLBCL and BL. These results emphasize the significant biological heterogeneity and the development of cytogenetic risk adapted therapy in childhood mature-B-NHL.
Url:
DOI: 10.1038/leu.2008.312
PubMed: 19020548
PubMed Central: 2988438
Affiliations:
- Belgique, France, Royaume-Uni, États-Unis
- Californie, Région de Bruxelles-Capitale, Utah, État de New York, Île-de-France
- Bobigny, Bruxelles, Los Angeles, New York
- Université Columbia, Université Paris 13, Université de Californie du Sud
Links toward previous steps (curation, corpus...)
Links to Exploration step
PMC:2988438Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell Non-Hodgkin’s Lymphoma: Results of the FAB/LMB 96 international study</title><author><name sortKey="Poirel, Ha" sort="Poirel, Ha" uniqKey="Poirel H" first="Ha" last="Poirel">Ha Poirel</name><affiliation wicri:level="4"><nlm:aff id="A1">Biological Hematology, CHU Avicenne – Université Paris 13, Bobigny, France</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>Biological Hematology, CHU Avicenne – Université Paris 13, Bobigny</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Bobigny</settlement></placeName><orgName type="university">Université Paris 13</orgName></affiliation><affiliation wicri:level="3"><nlm:aff id="A2">Cliniques Universitaire Saint-Luc UCL & de Duve Institute, Hematological Genetics & Human Molecular Genetics (GEHU), Brussels, Belgium</nlm:aff><country xml:lang="fr">Belgique</country><wicri:regionArea>Cliniques Universitaire Saint-Luc UCL & de Duve Institute, Hematological Genetics & Human Molecular Genetics (GEHU), Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="Cairo, Ms" sort="Cairo, Ms" uniqKey="Cairo M" first="Ms" last="Cairo">Ms Cairo</name><affiliation wicri:level="4"><nlm:aff id="A3">Division of Pediatric Blood and Marrow Transplantation, Morgan Stanley Children’s Hospital of New York Presbyterian, Columbia University, New York, NY-USA</nlm:aff><orgName type="university">Université Columbia</orgName><country>États-Unis</country><placeName><settlement type="city">New York</settlement><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Heerema, Na" sort="Heerema, Na" uniqKey="Heerema N" first="Na" last="Heerema">Na Heerema</name><affiliation><nlm:aff id="A4">Department of Pathology - Cytogenetics, The Ohio State University, Columbus, OH-USA</nlm:aff><wicri:noCountry code="subfield">OH-USA</wicri:noCountry></affiliation></author><author><name sortKey="Swansbury, J" sort="Swansbury, J" uniqKey="Swansbury J" first="J" last="Swansbury">J. Swansbury</name><affiliation wicri:level="1"><nlm:aff id="A5">Haematology Cytogenetics, The Royal Marsden Hospital, Sutton, UK</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Haematology Cytogenetics, The Royal Marsden Hospital, Sutton</wicri:regionArea><wicri:noRegion>Sutton</wicri:noRegion></affiliation></author><author><name sortKey="Auperin, A" sort="Auperin, A" uniqKey="Auperin A" first="A" last="Aupérin">A. Aupérin</name><affiliation wicri:level="1"><nlm:aff id="A6">Department of Biostatistics, Institut Gustave Roussy, Villejuif, France</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>Department of Biostatistics, Institut Gustave Roussy, Villejuif</wicri:regionArea><wicri:noRegion>Villejuif</wicri:noRegion><wicri:noRegion>Villejuif</wicri:noRegion></affiliation></author><author><name sortKey="Launay, E" sort="Launay, E" uniqKey="Launay E" first="E" last="Launay">E. Launay</name><affiliation wicri:level="4"><nlm:aff id="A1">Biological Hematology, CHU Avicenne – Université Paris 13, Bobigny, France</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>Biological Hematology, CHU Avicenne – Université Paris 13, Bobigny</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Bobigny</settlement></placeName><orgName type="university">Université Paris 13</orgName></affiliation></author><author><name sortKey="Sanger, Wg" sort="Sanger, Wg" uniqKey="Sanger W" first="Wg" last="Sanger">Wg Sanger</name><affiliation><nlm:aff id="A7">Human Genetics Laboratory, University of Nebraska Medical Center, Omaha, NE-USA</nlm:aff><wicri:noCountry code="subfield">NE-USA</wicri:noCountry></affiliation></author><author><name sortKey="Talley, P" sort="Talley, P" uniqKey="Talley P" first="P" last="Talley">P. Talley</name><affiliation wicri:level="1"><nlm:aff id="A8">Cytogenetics, Sheffield Children’s Hospital, Sheffield, UK</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Cytogenetics, Sheffield Children’s Hospital, Sheffield</wicri:regionArea><wicri:noRegion>Sheffield</wicri:noRegion></affiliation></author><author><name sortKey="Perkins, Sl" sort="Perkins, Sl" uniqKey="Perkins S" first="Sl" last="Perkins">Sl Perkins</name><affiliation wicri:level="2"><nlm:aff id="A9">Department of Pathology, University of Utah Health Sciences Center, Salt Lake City, Utah, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pathology, University of Utah Health Sciences Center, Salt Lake City, Utah</wicri:regionArea><placeName><region type="state">Utah</region></placeName></affiliation></author><author><name sortKey="Raphael, M" sort="Raphael, M" uniqKey="Raphael M" first="M" last="Raphaël">M. Raphaël</name><affiliation wicri:level="4"><nlm:aff id="A1">Biological Hematology, CHU Avicenne – Université Paris 13, Bobigny, France</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>Biological Hematology, CHU Avicenne – Université Paris 13, Bobigny</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Bobigny</settlement></placeName><orgName type="university">Université Paris 13</orgName></affiliation><affiliation wicri:level="1"><nlm:aff id="A10">Biological Hematology, CHU Bicêtre –Assistance Publique-Hôpitaux de Paris, INSERM U802, Université Paris-Sud 11, Le Kremlin-Bicêtre, France</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>Biological Hematology, CHU Bicêtre –Assistance Publique-Hôpitaux de Paris, INSERM U802, Université Paris-Sud 11, Le Kremlin-Bicêtre</wicri:regionArea><wicri:noRegion>Le Kremlin-Bicêtre</wicri:noRegion><wicri:noRegion>Le Kremlin-Bicêtre</wicri:noRegion></affiliation></author><author><name sortKey="Mccarthy, K" sort="Mccarthy, K" uniqKey="Mccarthy K" first="K" last="Mccarthy">K. Mccarthy</name><affiliation wicri:level="1"><nlm:aff id="A11">Department of Pathology, Gloucestershire Hospitals, NHS Foundation, Gloucestershire, UK</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Pathology, Gloucestershire Hospitals, NHS Foundation, Gloucestershire</wicri:regionArea><wicri:noRegion>Gloucestershire</wicri:noRegion></affiliation></author><author><name sortKey="Sposto, R" sort="Sposto, R" uniqKey="Sposto R" first="R" last="Sposto">R. Sposto</name><affiliation wicri:level="4"><nlm:aff id="A12">Department of Biostatistics, Children’s Hospital Los Angeles, University of Southern California, Los Angeles, CA-USA</nlm:aff><orgName type="university">Université de Californie du Sud</orgName><country>États-Unis</country><placeName><settlement type="city">Los Angeles</settlement><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Gerrard, M" sort="Gerrard, M" uniqKey="Gerrard M" first="M" last="Gerrard">M. Gerrard</name><affiliation wicri:level="1"><nlm:aff id="A13">Department of Paediatric Oncology, Sheffield Children’s Hospital, Sheffield, UK</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Paediatric Oncology, Sheffield Children’s Hospital, Sheffield</wicri:regionArea><wicri:noRegion>Sheffield</wicri:noRegion></affiliation></author><author><name sortKey="Bernheim, A" sort="Bernheim, A" uniqKey="Bernheim A" first="A" last="Bernheim">A. Bernheim</name><affiliation wicri:level="1"><nlm:aff id="A14">Laboratoire de genomique cellulaire des cancers, Institut Gustave Roussy, Villejuif, France</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire de genomique cellulaire des cancers, Institut Gustave Roussy, Villejuif</wicri:regionArea><wicri:noRegion>Villejuif</wicri:noRegion><wicri:noRegion>Villejuif</wicri:noRegion></affiliation></author><author><name sortKey="Patte, C" sort="Patte, C" uniqKey="Patte C" first="C" last="Patte">C. Patte</name><affiliation wicri:level="1"><nlm:aff id="A15">Department of Pediatric onco-hematology, Institut Gustave Roussy, Villejuif, France</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>Department of Pediatric onco-hematology, Institut Gustave Roussy, Villejuif</wicri:regionArea><wicri:noRegion>Villejuif</wicri:noRegion><wicri:noRegion>Villejuif</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">19020548</idno><idno type="pmc">2988438</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2988438</idno><idno type="RBID">PMC:2988438</idno><idno type="doi">10.1038/leu.2008.312</idno><date when="2008">2008</date><idno type="wicri:Area/Pmc/Corpus">000217</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000217</idno><idno type="wicri:Area/Pmc/Curation">000217</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000217</idno><idno type="wicri:Area/Pmc/Checkpoint">000030</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000030</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell Non-Hodgkin’s Lymphoma: Results of the FAB/LMB 96 international study</title><author><name sortKey="Poirel, Ha" sort="Poirel, Ha" uniqKey="Poirel H" first="Ha" last="Poirel">Ha Poirel</name><affiliation wicri:level="4"><nlm:aff id="A1">Biological Hematology, CHU Avicenne – Université Paris 13, Bobigny, France</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>Biological Hematology, CHU Avicenne – Université Paris 13, Bobigny</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Bobigny</settlement></placeName><orgName type="university">Université Paris 13</orgName></affiliation><affiliation wicri:level="3"><nlm:aff id="A2">Cliniques Universitaire Saint-Luc UCL & de Duve Institute, Hematological Genetics & Human Molecular Genetics (GEHU), Brussels, Belgium</nlm:aff><country xml:lang="fr">Belgique</country><wicri:regionArea>Cliniques Universitaire Saint-Luc UCL & de Duve Institute, Hematological Genetics & Human Molecular Genetics (GEHU), Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="Cairo, Ms" sort="Cairo, Ms" uniqKey="Cairo M" first="Ms" last="Cairo">Ms Cairo</name><affiliation wicri:level="4"><nlm:aff id="A3">Division of Pediatric Blood and Marrow Transplantation, Morgan Stanley Children’s Hospital of New York Presbyterian, Columbia University, New York, NY-USA</nlm:aff><orgName type="university">Université Columbia</orgName><country>États-Unis</country><placeName><settlement type="city">New York</settlement><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Heerema, Na" sort="Heerema, Na" uniqKey="Heerema N" first="Na" last="Heerema">Na Heerema</name><affiliation><nlm:aff id="A4">Department of Pathology - Cytogenetics, The Ohio State University, Columbus, OH-USA</nlm:aff><wicri:noCountry code="subfield">OH-USA</wicri:noCountry></affiliation></author><author><name sortKey="Swansbury, J" sort="Swansbury, J" uniqKey="Swansbury J" first="J" last="Swansbury">J. Swansbury</name><affiliation wicri:level="1"><nlm:aff id="A5">Haematology Cytogenetics, The Royal Marsden Hospital, Sutton, UK</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Haematology Cytogenetics, The Royal Marsden Hospital, Sutton</wicri:regionArea><wicri:noRegion>Sutton</wicri:noRegion></affiliation></author><author><name sortKey="Auperin, A" sort="Auperin, A" uniqKey="Auperin A" first="A" last="Aupérin">A. Aupérin</name><affiliation wicri:level="1"><nlm:aff id="A6">Department of Biostatistics, Institut Gustave Roussy, Villejuif, France</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>Department of Biostatistics, Institut Gustave Roussy, Villejuif</wicri:regionArea><wicri:noRegion>Villejuif</wicri:noRegion><wicri:noRegion>Villejuif</wicri:noRegion></affiliation></author><author><name sortKey="Launay, E" sort="Launay, E" uniqKey="Launay E" first="E" last="Launay">E. Launay</name><affiliation wicri:level="4"><nlm:aff id="A1">Biological Hematology, CHU Avicenne – Université Paris 13, Bobigny, France</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>Biological Hematology, CHU Avicenne – Université Paris 13, Bobigny</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Bobigny</settlement></placeName><orgName type="university">Université Paris 13</orgName></affiliation></author><author><name sortKey="Sanger, Wg" sort="Sanger, Wg" uniqKey="Sanger W" first="Wg" last="Sanger">Wg Sanger</name><affiliation><nlm:aff id="A7">Human Genetics Laboratory, University of Nebraska Medical Center, Omaha, NE-USA</nlm:aff><wicri:noCountry code="subfield">NE-USA</wicri:noCountry></affiliation></author><author><name sortKey="Talley, P" sort="Talley, P" uniqKey="Talley P" first="P" last="Talley">P. Talley</name><affiliation wicri:level="1"><nlm:aff id="A8">Cytogenetics, Sheffield Children’s Hospital, Sheffield, UK</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Cytogenetics, Sheffield Children’s Hospital, Sheffield</wicri:regionArea><wicri:noRegion>Sheffield</wicri:noRegion></affiliation></author><author><name sortKey="Perkins, Sl" sort="Perkins, Sl" uniqKey="Perkins S" first="Sl" last="Perkins">Sl Perkins</name><affiliation wicri:level="2"><nlm:aff id="A9">Department of Pathology, University of Utah Health Sciences Center, Salt Lake City, Utah, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pathology, University of Utah Health Sciences Center, Salt Lake City, Utah</wicri:regionArea><placeName><region type="state">Utah</region></placeName></affiliation></author><author><name sortKey="Raphael, M" sort="Raphael, M" uniqKey="Raphael M" first="M" last="Raphaël">M. Raphaël</name><affiliation wicri:level="4"><nlm:aff id="A1">Biological Hematology, CHU Avicenne – Université Paris 13, Bobigny, France</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>Biological Hematology, CHU Avicenne – Université Paris 13, Bobigny</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Bobigny</settlement></placeName><orgName type="university">Université Paris 13</orgName></affiliation><affiliation wicri:level="1"><nlm:aff id="A10">Biological Hematology, CHU Bicêtre –Assistance Publique-Hôpitaux de Paris, INSERM U802, Université Paris-Sud 11, Le Kremlin-Bicêtre, France</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>Biological Hematology, CHU Bicêtre –Assistance Publique-Hôpitaux de Paris, INSERM U802, Université Paris-Sud 11, Le Kremlin-Bicêtre</wicri:regionArea><wicri:noRegion>Le Kremlin-Bicêtre</wicri:noRegion><wicri:noRegion>Le Kremlin-Bicêtre</wicri:noRegion></affiliation></author><author><name sortKey="Mccarthy, K" sort="Mccarthy, K" uniqKey="Mccarthy K" first="K" last="Mccarthy">K. Mccarthy</name><affiliation wicri:level="1"><nlm:aff id="A11">Department of Pathology, Gloucestershire Hospitals, NHS Foundation, Gloucestershire, UK</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Pathology, Gloucestershire Hospitals, NHS Foundation, Gloucestershire</wicri:regionArea><wicri:noRegion>Gloucestershire</wicri:noRegion></affiliation></author><author><name sortKey="Sposto, R" sort="Sposto, R" uniqKey="Sposto R" first="R" last="Sposto">R. Sposto</name><affiliation wicri:level="4"><nlm:aff id="A12">Department of Biostatistics, Children’s Hospital Los Angeles, University of Southern California, Los Angeles, CA-USA</nlm:aff><orgName type="university">Université de Californie du Sud</orgName><country>États-Unis</country><placeName><settlement type="city">Los Angeles</settlement><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Gerrard, M" sort="Gerrard, M" uniqKey="Gerrard M" first="M" last="Gerrard">M. Gerrard</name><affiliation wicri:level="1"><nlm:aff id="A13">Department of Paediatric Oncology, Sheffield Children’s Hospital, Sheffield, UK</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Paediatric Oncology, Sheffield Children’s Hospital, Sheffield</wicri:regionArea><wicri:noRegion>Sheffield</wicri:noRegion></affiliation></author><author><name sortKey="Bernheim, A" sort="Bernheim, A" uniqKey="Bernheim A" first="A" last="Bernheim">A. Bernheim</name><affiliation wicri:level="1"><nlm:aff id="A14">Laboratoire de genomique cellulaire des cancers, Institut Gustave Roussy, Villejuif, France</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire de genomique cellulaire des cancers, Institut Gustave Roussy, Villejuif</wicri:regionArea><wicri:noRegion>Villejuif</wicri:noRegion><wicri:noRegion>Villejuif</wicri:noRegion></affiliation></author><author><name sortKey="Patte, C" sort="Patte, C" uniqKey="Patte C" first="C" last="Patte">C. Patte</name><affiliation wicri:level="1"><nlm:aff id="A15">Department of Pediatric onco-hematology, Institut Gustave Roussy, Villejuif, France</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>Department of Pediatric onco-hematology, Institut Gustave Roussy, Villejuif</wicri:regionArea><wicri:noRegion>Villejuif</wicri:noRegion><wicri:noRegion>Villejuif</wicri:noRegion></affiliation></author></analytic><series><title level="j">Leukemia</title><idno type="ISSN">0887-6924</idno><idno type="eISSN">1476-5551</idno><imprint><date when="2008">2008</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p id="P1">Clinical studies showed that advanced stage, high LDH, poor response to reduction therapy and combined bone marrow and central nervous system disease are significantly associated with a decreased event free survival (EFS) in pediatric mature B-NHL treated on FAB/LMB96. Although rearranged MYC/8q24 (R8q24) is characteristic of Burkitt Lymphoma (BL), little information is available on other cytogenetic abnormalities and their prognostic importance. We performed an international review of 238 abnormal karyotypes in childhood mature-B-NHL treated on FAB/LMB96: 76% BL, 8% Burkitt-like lymphoma, 13% diffuse large B-cell lymphoma (DLBCL). The main BL R8q24 associated chromosomal aberrations were +1q [29%], +7q and del(13q) [14% each]. The DLBCL appeared heterogeneous and more complex. Incidence of R8q24 [34%] was higher than reported in adult DLBCL. The prognostic value of cytogenetic abnormalities on EFS was studied by Cox model controlling for the known risk factors: R8q24, +7q and del(13q) were independently associated with a significant inferior EFS [HR: 6.1 (p=0.030), 2.5 (p=0.015), 4.0 (p=0.0003), respectively]. The adverse prognosis of R8q24 was observed only in DLBCL while del(13q) and +7q had a similar effect in DLBCL and BL. These results emphasize the significant biological heterogeneity and the development of cytogenetic risk adapted therapy in childhood mature-B-NHL.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Patte, C" uniqKey="Patte C">C Patte</name></author><author><name sortKey="Auperin, A" uniqKey="Auperin A">A Auperin</name></author><author><name sortKey="Gerrard, M" uniqKey="Gerrard M">M Gerrard</name></author><author><name sortKey="Michon, J" uniqKey="Michon J">J Michon</name></author><author><name sortKey="Pinkerson, Cr" uniqKey="Pinkerson C">CR Pinkerson</name></author><author><name sortKey="Sposto, R" uniqKey="Sposto R">R Sposto</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cairo, Ms" uniqKey="Cairo M">MS Cairo</name></author><author><name sortKey="Gerrard, M" uniqKey="Gerrard M">M Gerrard</name></author><author><name sortKey="Sposto, R" uniqKey="Sposto R">R Sposto</name></author><author><name sortKey="Auperin, A" uniqKey="Auperin A">A Auperin</name></author><author><name sortKey="Pinkerson, Cr" uniqKey="Pinkerson C">CR Pinkerson</name></author><author><name sortKey="Michon, J" uniqKey="Michon J">J Michon</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gerrard, M" uniqKey="Gerrard M">M Gerrard</name></author><author><name sortKey="Cairo, Ms" uniqKey="Cairo M">MS Cairo</name></author><author><name sortKey="Weston, C" uniqKey="Weston C">C Weston</name></author><author><name sortKey="Auperin, A" uniqKey="Auperin A">A Auperin</name></author><author><name sortKey="Pinkerton, R" uniqKey="Pinkerton R">R Pinkerton</name></author><author><name sortKey="Lambilliote, A" uniqKey="Lambilliote A">A Lambilliote</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Harris, Nl" uniqKey="Harris N">NL Harris</name></author><author><name sortKey="Jaffe, Es" uniqKey="Jaffe E">ES Jaffe</name></author><author><name sortKey="Stein, H" uniqKey="Stein H">H Stein</name></author><author><name sortKey="Banks, Pm" uniqKey="Banks P">PM Banks</name></author><author><name sortKey="Chan, Jk" uniqKey="Chan J">JK Chan</name></author><author><name sortKey="Cleary, Ml" uniqKey="Cleary M">ML Cleary</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jaffe, Es" uniqKey="Jaffe E">ES Jaffe</name></author><author><name sortKey="Harris, Nl" uniqKey="Harris N">NL Harris</name></author><author><name sortKey="Stein, H" uniqKey="Stein H">H Stein</name></author><author><name sortKey="Vardiman, Jw" uniqKey="Vardiman J">JW Vardiman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lenoir, Gm" uniqKey="Lenoir G">GM Lenoir</name></author><author><name sortKey="Preud Omme, Jl" uniqKey="Preud Omme J">JL Preud’homme</name></author><author><name sortKey="Bernheim, A" uniqKey="Bernheim A">A Bernheim</name></author><author><name sortKey="Berger, R" uniqKey="Berger R">R Berger</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Battey, J" uniqKey="Battey J">J Battey</name></author><author><name sortKey="Moulding, C" uniqKey="Moulding C">C Moulding</name></author><author><name sortKey="Taub, R" uniqKey="Taub R">R Taub</name></author><author><name sortKey="Murphy, W" uniqKey="Murphy W">W Murphy</name></author><author><name sortKey="Stewart, T" uniqKey="Stewart T">T Stewart</name></author><author><name sortKey="Potter, H" uniqKey="Potter H">H Potter</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zech, L" uniqKey="Zech L">L Zech</name></author><author><name sortKey="Haglund, U" uniqKey="Haglund U">U Haglund</name></author><author><name sortKey="Nilsson, K" uniqKey="Nilsson K">K Nilsson</name></author><author><name sortKey="Klein, G" uniqKey="Klein G">G Klein</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bernheim, A" uniqKey="Bernheim A">A Bernheim</name></author><author><name sortKey="Berger, R" uniqKey="Berger R">R Berger</name></author><author><name sortKey="Lenoir, G" uniqKey="Lenoir G">G Lenoir</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Blum, Ka" uniqKey="Blum K">KA Blum</name></author><author><name sortKey="Lozanski, G" uniqKey="Lozanski G">G Lozanski</name></author><author><name sortKey="Byrd, Jc" uniqKey="Byrd J">JC Byrd</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wilda, M" uniqKey="Wilda M">M Wilda</name></author><author><name sortKey="Bruch, J" uniqKey="Bruch J">J Bruch</name></author><author><name sortKey="Harder, L" uniqKey="Harder L">L Harder</name></author><author><name sortKey="Rawer, D" uniqKey="Rawer D">D Rawer</name></author><author><name sortKey="Reiter, A" uniqKey="Reiter A">A Reiter</name></author><author><name sortKey="Borkhardt, A" uniqKey="Borkhardt A">A Borkhardt</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lindstrom, Ms" uniqKey="Lindstrom M">MS Lindstrom</name></author><author><name sortKey="Wiman, Kg" uniqKey="Wiman K">KG Wiman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Berger, R" uniqKey="Berger R">R Berger</name></author><author><name sortKey="Bernheim, A" uniqKey="Bernheim A">A Bernheim</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Berger, R" uniqKey="Berger R">R Berger</name></author><author><name sortKey="Le Coniat, M" uniqKey="Le Coniat M">M Le Coniat</name></author><author><name sortKey="Derre, J" uniqKey="Derre J">J Derre</name></author><author><name sortKey="Vecchione, D" uniqKey="Vecchione D">D Vecchione</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lai, Jl" uniqKey="Lai J">JL Lai</name></author><author><name sortKey="Fenaux, P" uniqKey="Fenaux P">P Fenaux</name></author><author><name sortKey="Zandecki, M" uniqKey="Zandecki M">M Zandecki</name></author><author><name sortKey="Nelken, B" uniqKey="Nelken B">B Nelken</name></author><author><name sortKey="Huart, Jj" uniqKey="Huart J">JJ Huart</name></author><author><name sortKey="Deminatti, M" uniqKey="Deminatti M">M Deminatti</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kornblau, Sm" uniqKey="Kornblau S">SM Kornblau</name></author><author><name sortKey="Goodacre, A" uniqKey="Goodacre A">A Goodacre</name></author><author><name sortKey="Cabanillas, F" uniqKey="Cabanillas F">F Cabanillas</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Johansson, B" uniqKey="Johansson B">B Johansson</name></author><author><name sortKey="Mertens, F" uniqKey="Mertens F">F Mertens</name></author><author><name sortKey="Mitelman, F" uniqKey="Mitelman F">F Mitelman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Berger, R" uniqKey="Berger R">R Berger</name></author><author><name sortKey="Bernheim, A" uniqKey="Bernheim A">A Bernheim</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Knutsen, T" uniqKey="Knutsen T">T Knutsen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Garcia, Jl" uniqKey="Garcia J">JL Garcia</name></author><author><name sortKey="Hernandez, Jm" uniqKey="Hernandez J">JM Hernandez</name></author><author><name sortKey="Gutierrez, Nc" uniqKey="Gutierrez N">NC Gutierrez</name></author><author><name sortKey="Flores, T" uniqKey="Flores T">T Flores</name></author><author><name sortKey="Gonzalez, D" uniqKey="Gonzalez D">D Gonzalez</name></author><author><name sortKey="Calasanz, Mj" uniqKey="Calasanz M">MJ Calasanz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lones, Ma" uniqKey="Lones M">MA Lones</name></author><author><name sortKey="Sanger, Wg" uniqKey="Sanger W">WG Sanger</name></author><author><name sortKey="Le Beau, Mm" uniqKey="Le Beau M">MM Le Beau</name></author><author><name sortKey="Heerema, Na" uniqKey="Heerema N">NA Heerema</name></author><author><name sortKey="Sposto, R" uniqKey="Sposto R">R Sposto</name></author><author><name sortKey="Perkins, Sl" uniqKey="Perkins S">SL Perkins</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Heerema, Na" uniqKey="Heerema N">NA Heerema</name></author><author><name sortKey="Bernheim, A" uniqKey="Bernheim A">A Bernheim</name></author><author><name sortKey="Lim, Ms" uniqKey="Lim M">MS Lim</name></author><author><name sortKey="Look, At" uniqKey="Look A">AT Look</name></author><author><name sortKey="Pasqualucci, L" uniqKey="Pasqualucci L">L Pasqualucci</name></author><author><name sortKey="Raetz, E" uniqKey="Raetz E">E Raetz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dave, Bj" uniqKey="Dave B">BJ Dave</name></author><author><name sortKey="Weisenburger, Dd" uniqKey="Weisenburger D">DD Weisenburger</name></author><author><name sortKey="Higgins, Cm" uniqKey="Higgins C">CM Higgins</name></author><author><name sortKey="Pickering, Dl" uniqKey="Pickering D">DL Pickering</name></author><author><name sortKey="Hess, Mm" uniqKey="Hess M">MM Hess</name></author><author><name sortKey="Chan, Wc" uniqKey="Chan W">WC Chan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Patte, C" uniqKey="Patte C">C Patte</name></author><author><name sortKey="Auperin, A" uniqKey="Auperin A">A Auperin</name></author><author><name sortKey="Michon, J" uniqKey="Michon J">J Michon</name></author><author><name sortKey="Behrendt, H" uniqKey="Behrendt H">H Behrendt</name></author><author><name sortKey="Leverger, G" uniqKey="Leverger G">G Leverger</name></author><author><name sortKey="Frappaz, D" uniqKey="Frappaz D">D Frappaz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lones, Ma" uniqKey="Lones M">MA Lones</name></author><author><name sortKey="Auperin, A" uniqKey="Auperin A">A Auperin</name></author><author><name sortKey="Raphael, M" uniqKey="Raphael M">M Raphael</name></author><author><name sortKey="Mccarthy, K" uniqKey="Mccarthy K">K McCarthy</name></author><author><name sortKey="Perkins, Sl" uniqKey="Perkins S">SL Perkins</name></author><author><name sortKey="Maclennan, Ka" uniqKey="Maclennan K">KA MacLennan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shaffer, Lg" uniqKey="Shaffer L">LG Shaffer</name></author><author><name sortKey="Tommerup, N" uniqKey="Tommerup N">N Tommerup</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Reiter, A" uniqKey="Reiter A">A Reiter</name></author><author><name sortKey="Schrappe, M" uniqKey="Schrappe M">M Schrappe</name></author><author><name sortKey="Tiemann, M" uniqKey="Tiemann M">M Tiemann</name></author><author><name sortKey="Ludwig, Wd" uniqKey="Ludwig W">WD Ludwig</name></author><author><name sortKey="Yakisan, E" uniqKey="Yakisan E">E Yakisan</name></author><author><name sortKey="Zimmermann, M" uniqKey="Zimmermann M">M Zimmermann</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Barin, C" uniqKey="Barin C">C Barin</name></author><author><name sortKey="Valtat, C" uniqKey="Valtat C">C Valtat</name></author><author><name sortKey="Briault, S" uniqKey="Briault S">S Briault</name></author><author><name sortKey="Bremont, Jl" uniqKey="Bremont J">JL Bremont</name></author><author><name sortKey="Petit, A" uniqKey="Petit A">A Petit</name></author><author><name sortKey="Lejars, O" uniqKey="Lejars O">O Lejars</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ogden, Ca" uniqKey="Ogden C">CA Ogden</name></author><author><name sortKey="Pound, Jd" uniqKey="Pound J">JD Pound</name></author><author><name sortKey="Batth, Bk" uniqKey="Batth B">BK Batth</name></author><author><name sortKey="Owens, S" uniqKey="Owens S">S Owens</name></author><author><name sortKey="Johannessen, I" uniqKey="Johannessen I">I Johannessen</name></author><author><name sortKey="Wood, K" uniqKey="Wood K">K Wood</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Calin, Ga" uniqKey="Calin G">GA Calin</name></author><author><name sortKey="Liu, Cg" uniqKey="Liu C">CG Liu</name></author><author><name sortKey="Sevignani, C" uniqKey="Sevignani C">C Sevignani</name></author><author><name sortKey="Ferracin, M" uniqKey="Ferracin M">M Ferracin</name></author><author><name sortKey="Felli, N" uniqKey="Felli N">N Felli</name></author><author><name sortKey="Dumitru, Cd" uniqKey="Dumitru C">CD Dumitru</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hummel, M" uniqKey="Hummel M">M Hummel</name></author><author><name sortKey="Bentink, S" uniqKey="Bentink S">S Bentink</name></author><author><name sortKey="Berger, H" uniqKey="Berger H">H Berger</name></author><author><name sortKey="Klapper, W" uniqKey="Klapper W">W Klapper</name></author><author><name sortKey="Wessendorf, S" uniqKey="Wessendorf S">S Wessendorf</name></author><author><name sortKey="Barth, Tf" uniqKey="Barth T">TF Barth</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dave, Ss" uniqKey="Dave S">SS Dave</name></author><author><name sortKey="Fu, K" uniqKey="Fu K">K Fu</name></author><author><name sortKey="Wright, Gw" uniqKey="Wright G">GW Wright</name></author><author><name sortKey="Lam, Lt" uniqKey="Lam L">LT Lam</name></author><author><name sortKey="Kluin, P" uniqKey="Kluin P">P Kluin</name></author><author><name sortKey="Boerma, Ej" uniqKey="Boerma E">EJ Boerma</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kawasaki, C" uniqKey="Kawasaki C">C Kawasaki</name></author><author><name sortKey="Ohshim, K" uniqKey="Ohshim K">K Ohshim</name></author><author><name sortKey="Suzumiya, J" uniqKey="Suzumiya J">J Suzumiya</name></author><author><name sortKey="Kanda, M" uniqKey="Kanda M">M Kanda</name></author><author><name sortKey="Tsuchiya, T" uniqKey="Tsuchiya T">T Tsuchiya</name></author><author><name sortKey="Tamura, K" uniqKey="Tamura K">K Tamura</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Akasaka, T" uniqKey="Akasaka T">T Akasaka</name></author><author><name sortKey="Akasaka, H" uniqKey="Akasaka H">H Akasaka</name></author><author><name sortKey="Ueda, C" uniqKey="Ueda C">C Ueda</name></author><author><name sortKey="Kanda, M" uniqKey="Kanda M">M Kanda</name></author><author><name sortKey="Tsuchiya, T" uniqKey="Tsuchiya T">T Tsuchiya</name></author><author><name sortKey="Tamura, K" uniqKey="Tamura K">K Tamura</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Miles, R" uniqKey="Miles R">R Miles</name></author><author><name sortKey="Raphael, M" uniqKey="Raphael M">M Raphael</name></author><author><name sortKey="Mccarthy, K" uniqKey="Mccarthy K">K McCarthy</name></author><author><name sortKey="Wotherspoon, A" uniqKey="Wotherspoon A">A Wotherspoon</name></author><author><name sortKey="Lones, M" uniqKey="Lones M">M Lones</name></author><author><name sortKey="Cairo, M" uniqKey="Cairo M">M Cairo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Oschlies, I" uniqKey="Oschlies I">I Oschlies</name></author><author><name sortKey="Klapper, W" uniqKey="Klapper W">W Klapper</name></author><author><name sortKey="Zimmermann, M" uniqKey="Zimmermann M">M Zimmermann</name></author><author><name sortKey="Krams, M" uniqKey="Krams M">M Krams</name></author><author><name sortKey="Wacker, Hh" uniqKey="Wacker H">HH Wacker</name></author><author><name sortKey="Burkhardt, B" uniqKey="Burkhardt B">B Burkhardt</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rosenwald, A" uniqKey="Rosenwald A">A Rosenwald</name></author><author><name sortKey="Wright, G" uniqKey="Wright G">G Wright</name></author><author><name sortKey="Chan, Wc" uniqKey="Chan W">WC Chan</name></author><author><name sortKey="Connors, Jm" uniqKey="Connors J">JM Connors</name></author><author><name sortKey="Campo, E" uniqKey="Campo E">E Campo</name></author><author><name sortKey="Fisher, Ri" uniqKey="Fisher R">RI Fisher</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<pmc-dir>properties manuscript</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-journal-id">8704895</journal-id><journal-id journal-id-type="pubmed-jr-id">5536</journal-id><journal-id journal-id-type="nlm-ta">Leukemia</journal-id><journal-id journal-id-type="iso-abbrev">Leukemia</journal-id><journal-title-group><journal-title>Leukemia</journal-title></journal-title-group><issn pub-type="ppub">0887-6924</issn><issn pub-type="epub">1476-5551</issn></journal-meta><article-meta><article-id pub-id-type="pmid">19020548</article-id><article-id pub-id-type="pmc">2988438</article-id><article-id pub-id-type="doi">10.1038/leu.2008.312</article-id><article-id pub-id-type="manuscript">NIHMS107551</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell Non-Hodgkin’s Lymphoma: Results of the FAB/LMB 96 international study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Poirel</surname><given-names>HA</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref><xref rid="FN2" ref-type="author-notes">17</xref></contrib><contrib contrib-type="author"><name><surname>Cairo</surname><given-names>MS</given-names></name><xref ref-type="aff" rid="A3">3</xref><xref rid="FN2" ref-type="author-notes">17</xref></contrib><contrib contrib-type="author"><name><surname>Heerema</surname><given-names>NA</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Swansbury</surname><given-names>J</given-names></name><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Aupérin</surname><given-names>A</given-names></name><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name><surname>Launay</surname><given-names>E</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sanger</surname><given-names>WG</given-names></name><xref ref-type="aff" rid="A7">7</xref></contrib><contrib contrib-type="author"><name><surname>Talley</surname><given-names>P</given-names></name><xref ref-type="aff" rid="A8">8</xref></contrib><contrib contrib-type="author"><name><surname>Perkins</surname><given-names>SL</given-names></name><xref ref-type="aff" rid="A9">9</xref></contrib><contrib contrib-type="author"><name><surname>Raphaël</surname><given-names>M</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A10">10</xref></contrib><contrib contrib-type="author"><name><surname>McCarthy</surname><given-names>K</given-names></name><xref ref-type="aff" rid="A11">11</xref></contrib><contrib contrib-type="author"><name><surname>Sposto</surname><given-names>R</given-names></name><xref ref-type="aff" rid="A12">12</xref></contrib><contrib contrib-type="author"><name><surname>Gerrard</surname><given-names>M</given-names></name><xref ref-type="aff" rid="A13">13</xref></contrib><contrib contrib-type="author"><name><surname>Bernheim</surname><given-names>A</given-names></name><xref ref-type="aff" rid="A14">14</xref></contrib><contrib contrib-type="author"><name><surname>Patte</surname><given-names>C</given-names></name><xref ref-type="aff" rid="A15">15</xref></contrib><on-behalf-of>FAB LMB 96 International Study Committee</on-behalf-of><xref ref-type="aff" rid="A16">16</xref></contrib-group><aff id="A1"><label>1</label>Biological Hematology, CHU Avicenne – Université Paris 13, Bobigny, France</aff><aff id="A2"><label>2</label>Cliniques Universitaire Saint-Luc UCL & de Duve Institute, Hematological Genetics & Human Molecular Genetics (GEHU), Brussels, Belgium</aff><aff id="A3"><label>3</label>Division of Pediatric Blood and Marrow Transplantation, Morgan Stanley Children’s Hospital of New York Presbyterian, Columbia University, New York, NY-USA</aff><aff id="A4"><label>4</label>Department of Pathology - Cytogenetics, The Ohio State University, Columbus, OH-USA</aff><aff id="A5"><label>5</label>Haematology Cytogenetics, The Royal Marsden Hospital, Sutton, UK</aff><aff id="A6"><label>6</label>Department of Biostatistics, Institut Gustave Roussy, Villejuif, France</aff><aff id="A7"><label>7</label>Human Genetics Laboratory, University of Nebraska Medical Center, Omaha, NE-USA</aff><aff id="A8"><label>8</label>Cytogenetics, Sheffield Children’s Hospital, Sheffield, UK</aff><aff id="A9"><label>9</label>Department of Pathology, University of Utah Health Sciences Center, Salt Lake City, Utah, USA</aff><aff id="A10"><label>10</label>Biological Hematology, CHU Bicêtre –Assistance Publique-Hôpitaux de Paris, INSERM U802, Université Paris-Sud 11, Le Kremlin-Bicêtre, France</aff><aff id="A11"><label>11</label>Department of Pathology, Gloucestershire Hospitals, NHS Foundation, Gloucestershire, UK</aff><aff id="A12"><label>12</label>Department of Biostatistics, Children’s Hospital Los Angeles, University of Southern California, Los Angeles, CA-USA</aff><aff id="A13"><label>13</label>Department of Paediatric Oncology, Sheffield Children’s Hospital, Sheffield, UK</aff><aff id="A14"><label>14</label>Laboratoire de genomique cellulaire des cancers, Institut Gustave Roussy, Villejuif, France</aff><aff id="A15"><label>15</label>Department of Pediatric onco-hematology, Institut Gustave Roussy, Villejuif, France</aff><aff id="A16"><label>16</label>Children’s Oncology Group (COG), Arcadia, CA, USA, Société Française d’Oncologie Pédiatrique (SFOP), France, and the United Kingdom Children’s Cancer Study Group (UKCCSG), Leicester, UK</aff><author-notes><corresp id="FN1">Correspondence Pr Hélène A Poirel, MD PhD, c/o Société Française des Cancers de l’enfant, <email>helene.antoine-poirel@uclouvain.be</email>, Hematological Genetics & Human Molecular Genetics (GEHU), Cliniques Universitaire Saint-Luc UCL & de Duve Institute, avenue Mounier, F, B-1200 Brussels - Belgium, Ph : +32 2 764 67 81, Fax: +32 2 764 69 36 <bold>and/or</bold> Pr Mitchell S. Cairo, MD, c/o <underline>Children’s</underline> Oncology Group Operations Office, <email>mc1310@columbia.edu</email>, Chief, Division of Pediatric Blood and Marrow Transplantation, Columbia University Medical Center, Morgan Stanley Children’s Hospital of New York Presbyterian, Columbia University, New York, NY-USA, Ph : +1 212 305 8316, Fax : +1 212 305 8428</corresp><fn id="FN2" fn-type="other"><label>17</label><p>should be considered co-primary first authors.</p></fn><fn id="FN3" fn-type="other"><p>A complete list of the participants in the cytogenetics study of the FAB/LMB96 International trial appears in the “Appendix”.</p></fn></author-notes><pub-date pub-type="nihms-submitted"><day>28</day><month>10</month><year>2010</year></pub-date><pub-date pub-type="epub"><day>20</day><month>11</month><year>2008</year></pub-date><pub-date pub-type="ppub"><month>2</month><year>2009</year></pub-date><pub-date pub-type="pmc-release"><day>19</day><month>11</month><year>2010</year></pub-date><volume>23</volume><issue>2</issue><fpage>323</fpage><lpage>331</lpage><pmc-comment>elocation-id from pubmed: 10.1038/leu.2008.312</pmc-comment>
<permissions><license xlink:href="http://www.nature.com/authors/editorial_policies/license.html#terms"><license-p>Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:<ext-link ext-link-type="uri" xlink:href="http://www.nature.com/authors/editorial_policies/license.html#terms">http://www.nature.com/authors/editorial_policies/license.html#terms</ext-link></license-p></license></permissions><abstract><p id="P1">Clinical studies showed that advanced stage, high LDH, poor response to reduction therapy and combined bone marrow and central nervous system disease are significantly associated with a decreased event free survival (EFS) in pediatric mature B-NHL treated on FAB/LMB96. Although rearranged MYC/8q24 (R8q24) is characteristic of Burkitt Lymphoma (BL), little information is available on other cytogenetic abnormalities and their prognostic importance. We performed an international review of 238 abnormal karyotypes in childhood mature-B-NHL treated on FAB/LMB96: 76% BL, 8% Burkitt-like lymphoma, 13% diffuse large B-cell lymphoma (DLBCL). The main BL R8q24 associated chromosomal aberrations were +1q [29%], +7q and del(13q) [14% each]. The DLBCL appeared heterogeneous and more complex. Incidence of R8q24 [34%] was higher than reported in adult DLBCL. The prognostic value of cytogenetic abnormalities on EFS was studied by Cox model controlling for the known risk factors: R8q24, +7q and del(13q) were independently associated with a significant inferior EFS [HR: 6.1 (p=0.030), 2.5 (p=0.015), 4.0 (p=0.0003), respectively]. The adverse prognosis of R8q24 was observed only in DLBCL while del(13q) and +7q had a similar effect in DLBCL and BL. These results emphasize the significant biological heterogeneity and the development of cytogenetic risk adapted therapy in childhood mature-B-NHL.</p></abstract><kwd-group><kwd>Childhood mature B-cell lymphoma</kwd><kwd>Burkitt lymphoma</kwd><kwd>DLBCL</kwd><kwd>cytogenetics</kwd><kwd>prognosis</kwd></kwd-group></article-meta></front><floats-group><fig id="F1" position="float"><label>Figure 1</label><caption><title>Distribution of cytogenetic abnormalities in FAB/LMB 96 Study stratified by histological subtypes Burkitt Lymphoma (BL), Burkitt Like Lymphoma (BLL) and Diffuse Large B-Cell Lymphoma (DLBCL)</title><p>R8q24, dup(1q), del(6q), der(11q), +12, ploidy and complexity are helpful in the discrimination between BL and DLBCL. BLL exhibit an intermediary pattern.</p></caption><graphic xlink:href="nihms107551f1"></graphic></fig><fig id="F2" position="float"><label>Figure 2</label><caption><title>Probability of EFS by Kaplan-Meier method in children with B-NHL treated on FAB/LMB 96 on the whole population (N=238)</title><p>Figure 2A: EFS with and without rearranged 8q24 cytogenetic abnormality</p><p>Figure 2B: EFS with and without del(13q) cytogenetic abnormality</p><p>Figure 2C: EFS with and without +7q cytogenetic abnormality</p><p>Figure 2D: EFS with and without a complex karyotype (>3 cytogenetic abnormalities)</p></caption><graphic xlink:href="nihms107551f2"></graphic></fig><fig id="F3" position="float"><label>Figure 3</label><caption><title>Probability of EFS by Kaplen-Meier method in children with B-NHL treated on FAB/LMB 96 according to the main morphologic entities BL (N=182) and DLBCL (N=30)</title><p>Figure 3A: EFS with and without rearranged 8q24 cytogenetic abnormality</p><p>Figure 3B: EFS with and without del(13q) cytogenetic abnormality</p><p>Figure 3C: EFS with and without +7q cytogenetic abnormality</p><p>Figure 3D: EFS with and without a complex karyotype (>3 cytogenetic abnormalities)</p><p>While del(13q), +7q and the complexity altered the prognosis of BL and DLBCL in the same proportion, the adverse effect of R8q24 is only detected in DLBCL.</p></caption><graphic xlink:href="nihms107551f3"></graphic></fig><table-wrap id="T1" position="float" orientation="landscape"><label>Table 1</label><caption><p>Initial patient characteristics of the 238 cases with cytogenetics Comparison with the other cases without cytogenetics of FAB/LMB96</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"></th><th align="center" colspan="2" valign="bottom" rowspan="1">With cytogenetics (N=238)</th><th align="center" colspan="2" valign="bottom" rowspan="1">Without cytogenetics (N=780)</th><th align="center" valign="bottom" rowspan="1" colspan="1">p<xref rid="TFN4" ref-type="table-fn">*</xref></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>M/F Sex ratio</bold></td><td align="center" colspan="2" rowspan="1">180/58 (3.1)</td><td align="center" colspan="2" rowspan="1">603/177 (3.4)</td><td align="center" rowspan="1" colspan="1">0.59</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Median age</bold>, years [range]</td><td align="center" colspan="2" rowspan="1">9.1 [2-20]</td><td align="center" colspan="2" rowspan="1">10.1 [1-20]</td><td align="center" rowspan="1" colspan="1">0.03<xref rid="TFN5" ref-type="table-fn">◦</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Therapeutic group</bold></td><td align="center" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1">0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1"> A</td><td align="center" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">(5%)</td><td align="left" rowspan="1" colspan="1">119</td><td align="left" rowspan="1" colspan="1">(15%)</td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> B</td><td align="center" rowspan="1" colspan="1">132</td><td align="left" rowspan="1" colspan="1">(55%)</td><td align="left" rowspan="1" colspan="1">550</td><td align="left" rowspan="1" colspan="1">(71%)</td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> C</td><td align="center" rowspan="1" colspan="1">95</td><td align="left" rowspan="1" colspan="1">(40%)</td><td align="left" rowspan="1" colspan="1">111</td><td align="left" rowspan="1" colspan="1">(14%)</td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Stage</bold></td><td align="center" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1">0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1"> I</td><td align="center" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">(5%)</td><td align="left" rowspan="1" colspan="1">104</td><td align="left" rowspan="1" colspan="1">(13%)</td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> II</td><td align="center" rowspan="1" colspan="1">26</td><td align="left" rowspan="1" colspan="1">(11%)</td><td align="left" rowspan="1" colspan="1">187</td><td align="left" rowspan="1" colspan="1">(24%)</td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> III</td><td align="center" rowspan="1" colspan="1">88</td><td align="left" rowspan="1" colspan="1">(37%)</td><td align="left" rowspan="1" colspan="1">358</td><td align="left" rowspan="1" colspan="1">(46%)</td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> IV</td><td align="center" rowspan="1" colspan="1">33</td><td align="left" rowspan="1" colspan="1">(14%)</td><td align="left" rowspan="1" colspan="1">61</td><td align="left" rowspan="1" colspan="1">(8%)</td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> Leukemia</td><td align="center" rowspan="1" colspan="1">80</td><td align="left" rowspan="1" colspan="1">(34%)</td><td align="left" rowspan="1" colspan="1">70</td><td align="left" rowspan="1" colspan="1">(9%)</td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>LDH</bold> > 2N</td><td align="center" rowspan="1" colspan="1">167</td><td align="left" rowspan="1" colspan="1">(71%)</td><td align="left" rowspan="1" colspan="1">244</td><td align="left" rowspan="1" colspan="1">(33%)</td><td align="center" rowspan="1" colspan="1">0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>CNS disease</bold></td><td align="center" rowspan="1" colspan="1">42</td><td align="left" rowspan="1" colspan="1">(18%)</td><td align="left" rowspan="1" colspan="1">65</td><td align="left" rowspan="1" colspan="1">(8%)</td><td align="center" rowspan="1" colspan="1">0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>COP response</bold> <20%</td><td align="center" rowspan="1" colspan="1">9/227</td><td align="left" rowspan="1" colspan="1">(4%)</td><td align="left" rowspan="1" colspan="1">31/658</td><td align="left" rowspan="1" colspan="1">(5%)</td><td align="center" rowspan="1" colspan="1">0.64</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Morphologic group</bold></td><td align="center" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1">0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1"> BL</td><td align="center" rowspan="1" colspan="1">182</td><td align="left" rowspan="1" colspan="1">(76%)</td><td align="left" rowspan="1" colspan="1">468</td><td align="left" rowspan="1" colspan="1">(60%)</td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> BLL</td><td align="center" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">(8%)</td><td align="left" rowspan="1" colspan="1">58</td><td align="left" rowspan="1" colspan="1">(7%)</td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> DLBCL</td><td align="center" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">(13%)</td><td align="left" rowspan="1" colspan="1">208</td><td align="left" rowspan="1" colspan="1">(26%)</td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> Not sub classified</td><td align="center" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">(3%)</td><td align="left" rowspan="1" colspan="1">46</td><td align="left" rowspan="1" colspan="1">(6%)</td><td align="center" rowspan="1" colspan="1"></td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>M/F : Male/Female</p></fn><fn id="TFN2"><p>CNS : central nervous system</p></fn><fn id="TFN3"><p>BL : Burkitt lymphoma, BLL : Burkitt-like lymphoma, DLBCL : diffuse large B-cell lymphoma</p></fn><fn id="TFN4"><label>*</label><p>chi-square test except for</p></fn><fn id="TFN5"><label>◦</label><p>Kruskal-Wallis test</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" position="float" orientation="landscape"><label>Table 2</label><caption><p>Prognostic significance of individual cytogenetic abnormalities (analysis of each abnormality separately)</p></caption><table frame="box" rules="all"><thead><tr><th align="left" rowspan="1" colspan="1"></th><th align="center" colspan="3" rowspan="1">Whole population</th><th align="center" colspan="3" rowspan="1">Burkitt lymphoma</th><th align="center" colspan="2" rowspan="1">DLBCL</th></tr><tr><th align="left" rowspan="1" colspan="1"></th><th align="center" colspan="3" rowspan="1">EFS (43 events / 238 patients)</th><th align="center" colspan="3" rowspan="1">EFS (30 events / 182 patients)</th><th align="center" colspan="2" rowspan="1">EFS (5 events / 30 patients)</th></tr><tr><th align="left" rowspan="1" colspan="1"></th><th align="center" valign="top" rowspan="1" colspan="1">Event / Patient</th><th align="center" valign="top" rowspan="1" colspan="1">HR [IC95%]</th><th align="center" valign="top" rowspan="1" colspan="1">p</th><th align="center" valign="top" rowspan="1" colspan="1">Event / Patient</th><th align="center" valign="top" rowspan="1" colspan="1">HR [IC95%]</th><th align="center" valign="top" rowspan="1" colspan="1">p</th><th align="center" valign="top" rowspan="1" colspan="1">Event / Patient</th><th align="center" valign="top" rowspan="1" colspan="1">p</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>R8q24</bold></td><td align="center" rowspan="1" colspan="1">41 / 201</td><td align="center" rowspan="1" colspan="1">5.4 [1.2-25]</td><td align="center" rowspan="1" colspan="1">0.03<xref rid="TFN6" ref-type="table-fn">*</xref></td><td align="center" rowspan="1" colspan="1">28 / 169</td><td align="center" rowspan="1" colspan="1">1.2 [0.26-5.2]</td><td align="center" rowspan="1" colspan="1">0.84<xref rid="TFN7" ref-type="table-fn">$</xref></td><td align="center" rowspan="1" colspan="1">5 / 10</td><td align="center" rowspan="1" colspan="1">0.0004<xref rid="TFN9" ref-type="table-fn">£</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"> N8q24</td><td align="center" rowspan="1" colspan="1">2 / 37</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> R8q24 alone</td><td align="center" rowspan="1" colspan="1">10 / 62</td><td align="center" rowspan="1" colspan="1">4.0 [0.75-21]</td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> R8q24 associated</td><td align="center" rowspan="1" colspan="1">31 / 139</td><td align="center" rowspan="1" colspan="1">5.7 [1.2-26]</td><td align="center" rowspan="1" colspan="1">0.06<xref rid="TFN6" ref-type="table-fn">*</xref></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>del(13q)</bold></td><td align="center" rowspan="1" colspan="1">12 / 33</td><td align="center" rowspan="1" colspan="1">4.3 [2.0-9.1]</td><td align="center" rowspan="1" colspan="1">0.0002<xref rid="TFN6" ref-type="table-fn">*</xref></td><td align="center" rowspan="1" colspan="1">8 / 26</td><td align="center" rowspan="1" colspan="1">4.8 [1.9-12]</td><td align="center" rowspan="1" colspan="1">0.001<xref rid="TFN7" ref-type="table-fn">$</xref></td><td align="center" rowspan="1" colspan="1">1 / 3</td><td align="center" rowspan="1" colspan="1">0.31<xref rid="TFN9" ref-type="table-fn">£</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>der(3q)</bold></td><td align="center" rowspan="1" colspan="1">5 / 13</td><td align="center" rowspan="1" colspan="1">3.1 [1.1-8.4]</td><td align="center" rowspan="1" colspan="1">0.03<xref rid="TFN6" ref-type="table-fn">*</xref></td><td align="center" rowspan="1" colspan="1">2 / 8</td><td align="center" rowspan="1" colspan="1">2.8 [0.60-12.8]</td><td align="center" rowspan="1" colspan="1">0.19<xref rid="TFN7" ref-type="table-fn">$</xref></td><td align="center" rowspan="1" colspan="1">2 / 4</td><td align="center" rowspan="1" colspan="1">0.02<xref rid="TFN9" ref-type="table-fn">£</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>+7q</bold></td><td align="center" rowspan="1" colspan="1">10 / 36</td><td align="center" rowspan="1" colspan="1">2.8 [1.4-5.9]</td><td align="center" rowspan="1" colspan="1">0.005<xref rid="TFN6" ref-type="table-fn">*</xref></td><td align="center" rowspan="1" colspan="1">6 / 25</td><td align="center" rowspan="1" colspan="1">2.6 [1.01-6.5]</td><td align="center" rowspan="1" colspan="1">0.047<xref rid="TFN7" ref-type="table-fn">$</xref></td><td align="center" rowspan="1" colspan="1">2 / 8</td><td align="center" rowspan="1" colspan="1">0.44<xref rid="TFN9" ref-type="table-fn">£</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>complexity</bold></td><td align="center" rowspan="1" colspan="1">24 /87</td><td align="center" rowspan="1" colspan="1">3.2 [1.7-6.1]</td><td align="center" rowspan="1" colspan="1">0.0005<xref rid="TFN6" ref-type="table-fn">*</xref></td><td align="center" rowspan="1" colspan="1">13 / 50</td><td align="center" rowspan="1" colspan="1">2.5 [1.2-5.2]</td><td align="center" rowspan="1" colspan="1">0.02<xref rid="TFN7" ref-type="table-fn">$</xref></td><td align="center" rowspan="1" colspan="1">5 / 24</td><td align="center" rowspan="1" colspan="1">0.24<xref rid="TFN9" ref-type="table-fn">£</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>aneuploidy</bold></td><td align="center" rowspan="1" colspan="1">21 / 86</td><td align="center" rowspan="1" colspan="1">2.1 [1.1-4.0]</td><td align="center" rowspan="1" colspan="1">0.02<xref rid="TFN6" ref-type="table-fn">*</xref></td><td align="center" rowspan="1" colspan="1">13 / 49</td><td align="center" rowspan="1" colspan="1">2.5 [1.2-5.4]</td><td align="center" rowspan="1" colspan="1">0.02<xref rid="TFN7" ref-type="table-fn">$</xref></td><td align="center" rowspan="1" colspan="1">3 / 24</td><td align="center" rowspan="1" colspan="1">0.19<xref rid="TFN9" ref-type="table-fn">£</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">+1q</td><td align="center" rowspan="1" colspan="1">8 / 65</td><td align="center" rowspan="1" colspan="1">0.53 [0.24-1.2]</td><td align="center" rowspan="1" colspan="1">0.11<xref rid="TFN6" ref-type="table-fn">*</xref></td><td align="center" rowspan="1" colspan="1">4 / 52</td><td align="center" rowspan="1" colspan="1">0.37 [0.13-1.1]</td><td align="center" rowspan="1" colspan="1">0.065<xref rid="TFN7" ref-type="table-fn">$</xref></td><td align="center" rowspan="1" colspan="1">1 / 4</td><td align="center" rowspan="1" colspan="1">0.63<xref rid="TFN9" ref-type="table-fn">£</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">del(6q)</td><td align="center" rowspan="1" colspan="1">6 / 33</td><td align="center" rowspan="1" colspan="1">0.97 [0.35-2.6]</td><td align="center" rowspan="1" colspan="1">0.95<xref rid="TFN6" ref-type="table-fn">*</xref></td><td align="center" rowspan="1" colspan="1">3 / 18</td><td align="center" rowspan="1" colspan="1">1.1 [0.32-3.7]</td><td align="center" rowspan="1" colspan="1">0.90<xref rid="TFN7" ref-type="table-fn">$</xref></td><td align="center" rowspan="1" colspan="1">3 / 13</td><td align="center" rowspan="1" colspan="1">0.38<xref rid="TFN9" ref-type="table-fn">£</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">der(9p)</td><td align="center" rowspan="1" colspan="1">0 / 7</td><td align="center" rowspan="1" colspan="1">/</td><td align="center" rowspan="1" colspan="1">0.37<xref rid="TFN8" ref-type="table-fn">◦</xref></td><td align="center" rowspan="1" colspan="1">0 / 5</td><td align="center" rowspan="1" colspan="1">/</td><td align="center" rowspan="1" colspan="1">0.48<xref rid="TFN8" ref-type="table-fn">◦</xref></td><td align="center" rowspan="1" colspan="1">0 / 2</td><td align="center" rowspan="1" colspan="1">0.53<xref rid="TFN9" ref-type="table-fn">£</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">der(11q)</td><td align="center" rowspan="1" colspan="1">3 / 19</td><td align="center" rowspan="1" colspan="1">0.96 [0.28-3.3]</td><td align="center" rowspan="1" colspan="1">0.95<xref rid="TFN6" ref-type="table-fn">*</xref></td><td align="center" rowspan="1" colspan="1">0 / 8</td><td align="center" rowspan="1" colspan="1">/</td><td align="center" rowspan="1" colspan="1">0.23<xref rid="TFN8" ref-type="table-fn">◦</xref></td><td align="center" rowspan="1" colspan="1">2 / 8</td><td align="center" rowspan="1" colspan="1">0.43<xref rid="TFN9" ref-type="table-fn">£</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">+12q</td><td align="center" rowspan="1" colspan="1">1 / 16</td><td align="center" rowspan="1" colspan="1">0.24 [0.03-1.9]</td><td align="center" rowspan="1" colspan="1">0.18<xref rid="TFN6" ref-type="table-fn">*</xref></td><td align="center" rowspan="1" colspan="1">0 / 6</td><td align="center" rowspan="1" colspan="1">/</td><td align="center" rowspan="1" colspan="1">0.28<xref rid="TFN8" ref-type="table-fn">◦</xref></td><td align="center" rowspan="1" colspan="1">0 / 7</td><td align="center" rowspan="1" colspan="1">0.20<xref rid="TFN9" ref-type="table-fn">£</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">del(17p)</td><td align="center" rowspan="1" colspan="1">6 / 21</td><td align="center" rowspan="1" colspan="1">1.4 [0.56-3.7]</td><td align="center" rowspan="1" colspan="1">0.45<xref rid="TFN6" ref-type="table-fn">*</xref></td><td align="center" rowspan="1" colspan="1">4 / 11</td><td align="center" rowspan="1" colspan="1">1.8 [0.63-5.4]</td><td align="center" rowspan="1" colspan="1">0.27<xref rid="TFN7" ref-type="table-fn">$</xref></td><td align="center" rowspan="1" colspan="1">1 / 7</td><td align="center" rowspan="1" colspan="1">0.85<xref rid="TFN9" ref-type="table-fn">£</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">der(18q)</td><td align="center" rowspan="1" colspan="1">3 / 10</td><td align="center" rowspan="1" colspan="1">2.1 [0.57-7.8]</td><td align="center" rowspan="1" colspan="1">0.27<xref rid="TFN6" ref-type="table-fn">*</xref></td><td align="center" rowspan="1" colspan="1">0 / 4</td><td align="center" rowspan="1" colspan="1">/</td><td align="center" rowspan="1" colspan="1">0.52<xref rid="TFN8" ref-type="table-fn">◦</xref></td><td align="center" rowspan="1" colspan="1">1 / 4</td><td align="center" rowspan="1" colspan="1">0.63<xref rid="TFN9" ref-type="table-fn">£</xref></td></tr></tbody></table><table-wrap-foot><fn id="TFN6"><label>*</label><p>Adjusted on
<list list-type="simple" id="L1"><list-item><p>- national cooperative group (SFOP vs CCG vs UKCCSG)</p></list-item><list-item><p>- therapeutic stratification group (C vs A / B)</p></list-item><list-item><p>- pathology (DLBCL vs BL / BLL / not sub classified)</p></list-item><list-item><p>- LDH level (>2N vs <=2N)</p></list-item><list-item><p>- CNS disease (yes vs no)</p></list-item><list-item><p>- primary mediastinal localisation (yes vs no)</p></list-item></list></p></fn><fn id="TFN7"><label>$</label><p>Adjusted on
<list list-type="simple" id="L2"><list-item><p>- national cooperative group (SFOP vs CCG vs UKCCSG)</p></list-item><list-item><p>- therapeutic stratification group (C vs A / B)</p></list-item><list-item><p>- LDH level (>2N vs <=2N)</p></list-item><list-item><p>- CNS disease (yes vs no)</p></list-item></list></p></fn><fn id="TFN8"><label>◦</label><p>Logrank test adjusted on LDH level and CNS disease</p></fn><fn id="TFN9"><label>£</label><p>Logrank test without any adjustment (due to the small number of events)</p></fn><fn id="TFN10"><p>HR : hazard ratio</p></fn></table-wrap-foot></table-wrap></floats-group></pmc><affiliations><list><country><li>Belgique</li><li>France</li><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Californie</li><li>Région de Bruxelles-Capitale</li><li>Utah</li><li>État de New York</li><li>Île-de-France</li></region><settlement><li>Bobigny</li><li>Bruxelles</li><li>Los Angeles</li><li>New York</li></settlement><orgName><li>Université Columbia</li><li>Université Paris 13</li><li>Université de Californie du Sud</li></orgName></list><tree><noCountry><name sortKey="Heerema, Na" sort="Heerema, Na" uniqKey="Heerema N" first="Na" last="Heerema">Na Heerema</name><name sortKey="Sanger, Wg" sort="Sanger, Wg" uniqKey="Sanger W" first="Wg" last="Sanger">Wg Sanger</name></noCountry><country name="France"><region name="Île-de-France"><name sortKey="Poirel, Ha" sort="Poirel, Ha" uniqKey="Poirel H" first="Ha" last="Poirel">Ha Poirel</name></region><name sortKey="Auperin, A" sort="Auperin, A" uniqKey="Auperin A" first="A" last="Aupérin">A. Aupérin</name><name sortKey="Bernheim, A" sort="Bernheim, A" uniqKey="Bernheim A" first="A" last="Bernheim">A. Bernheim</name><name sortKey="Launay, E" sort="Launay, E" uniqKey="Launay E" first="E" last="Launay">E. Launay</name><name sortKey="Patte, C" sort="Patte, C" uniqKey="Patte C" first="C" last="Patte">C. Patte</name><name sortKey="Raphael, M" sort="Raphael, M" uniqKey="Raphael M" first="M" last="Raphaël">M. Raphaël</name><name sortKey="Raphael, M" sort="Raphael, M" uniqKey="Raphael M" first="M" last="Raphaël">M. Raphaël</name></country><country name="Belgique"><region name="Région de Bruxelles-Capitale"><name sortKey="Poirel, Ha" sort="Poirel, Ha" uniqKey="Poirel H" first="Ha" last="Poirel">Ha Poirel</name></region></country><country name="États-Unis"><region name="État de New York"><name sortKey="Cairo, Ms" sort="Cairo, Ms" uniqKey="Cairo M" first="Ms" last="Cairo">Ms Cairo</name></region><name sortKey="Perkins, Sl" sort="Perkins, Sl" uniqKey="Perkins S" first="Sl" last="Perkins">Sl Perkins</name><name sortKey="Sposto, R" sort="Sposto, R" uniqKey="Sposto R" first="R" last="Sposto">R. Sposto</name></country><country name="Royaume-Uni"><noRegion><name sortKey="Swansbury, J" sort="Swansbury, J" uniqKey="Swansbury J" first="J" last="Swansbury">J. Swansbury</name></noRegion><name sortKey="Gerrard, M" sort="Gerrard, M" uniqKey="Gerrard M" first="M" last="Gerrard">M. Gerrard</name><name sortKey="Mccarthy, K" sort="Mccarthy, K" uniqKey="Mccarthy K" first="K" last="Mccarthy">K. Mccarthy</name><name sortKey="Talley, P" sort="Talley, P" uniqKey="Talley P" first="P" last="Talley">P. Talley</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Psychologie/explor/BernheimV1/Data/Pmc/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000030 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd -nk 000030 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Psychologie
|area= BernheimV1
|flux= Pmc
|étape= Checkpoint
|type= RBID
|clé= PMC:2988438
|texte= Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell Non-Hodgkin’s Lymphoma: Results of the FAB/LMB 96 international study
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/RBID.i -Sk "pubmed:19020548" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a BernheimV1
| This area was generated with Dilib version V0.6.33. |  |